TICKERNOMICS Sign up
Last Update: 2024-03-28 02:16:15
Paratek Pharmaceuticals Inc. ( PRTK ) https://paratekpharma.com
2.23USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
PRTK
15.54%
SPY
32.74%
-68.23%
PRTK
SPY
92.93%
-58.40%
PRTK
SPY
224.41%
-86.64%
PRTK
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
127.74
508.85
4.76
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.90
0.76
-0.63
4.41
0.00
-11.66
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-24.73
88.52
-30.44
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.6412
-16.07
-96.13
1.44
Other Earnings and Cash Flow Stats:
Paratek Pharmaceuticals Inc. ( PRTK ) Net Income TTM ($MM) is -69.05
Paratek Pharmaceuticals Inc. ( PRTK ) Operating Income TTM ($MM) is -41.91
Paratek Pharmaceuticals Inc. ( PRTK ) Owners' Earnings Annual ($MM) is -22.64
Paratek Pharmaceuticals Inc. ( PRTK ) Current Price to Owners' Earnings ratio is -5.64
Paratek Pharmaceuticals Inc. ( PRTK ) EBITDA TTM ($MM) is -41.11
Paratek Pharmaceuticals Inc. ( PRTK ) EBITDA Margin is -30.44%
Capital Allocation:
Paratek Pharmaceuticals Inc. ( PRTK ) has paid 0.00 dividends per share and bought back -2.894359 million shares in the past 12 months
Paratek Pharmaceuticals Inc. ( PRTK ) has reduced its debt by 93.03 million USD in the last 12 months
Capital Structure:
Paratek Pharmaceuticals Inc. ( PRTK ) Interest-bearing Debt ($MM) as of last quarter is 423
Paratek Pharmaceuticals Inc. ( PRTK ) Annual Working Capital Investments ($MM) are 23
Paratek Pharmaceuticals Inc. ( PRTK ) Book Value ($MM) as of last quarter is -202
Paratek Pharmaceuticals Inc. ( PRTK ) Debt/Capital as of last quarter is -211%
Other Balance Sheet Stats:
Paratek Pharmaceuticals Inc. ( PRTK ) has 42 million in cash on hand as of last quarter
Paratek Pharmaceuticals Inc. ( PRTK ) has 202 million of liabilities due within 12 months, and long term debt 258 as of last quarter
Paratek Pharmaceuticals Inc. ( PRTK ) has 57 common shares outstanding as of last quarter
Paratek Pharmaceuticals Inc. ( PRTK ) has 0 million USD of preferred stock value
Academic Scores:
Paratek Pharmaceuticals Inc. ( PRTK ) Altman Z-Score is -9.86 as of last quarter
Paratek Pharmaceuticals Inc. ( PRTK ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Paratek Pharmaceuticals Inc. ( PRTK ) largest shareholder is HIGHLAND CAPITAL MANAGEMENT FUND ADVISORS owning 2495770 shares at 5.57 ($MM) value
William M Haskel(an insider) Sold 34526 shares of Paratek Pharmaceuticals Inc. ( PRTK ) for the amount of $75957.20 on 2023-08-09
11.70% of Paratek Pharmaceuticals Inc. ( PRTK ) is held by insiders, and 55.08% is held by institutions
Paratek Pharmaceuticals Inc. ( PRTK ) went public on 2006-05-11
Other Paratek Pharmaceuticals Inc. ( PRTK ) financial metrics:
FCF:-48.92
Unlevered Free Cash Flow:-67.18
EPS:-1.02
Operating Margin:-24.73
Gross Profit Margin:88.52
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:28.91
Beta:1.44
Buffet's Owners Earnings:-22.64
Price to Owner's Earnings:-5.64
About Paratek Pharmaceuticals Inc. ( PRTK ) :
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.